

Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

Brilliant Violet 750(TM) anti-mouse/human CD11b

RRID:AB_2810328

Type: Antibody

Proper Citation

BioLegend Cat# 101267, RRID:AB_2810328

Antibody Information

URL: http://antibodyregistry.org/AB_2810328

Proper Citation: BioLegend Cat# 101267, RRID:AB_2810328

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 750(TM) anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_2810328

Vendor: BioLegend

Catalog Number: 101267

Record Creation Time: 20250819T232002+0000

Record Last Update: 20250820T050141+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 750(TM) anti-mouse/human CD11b.

No alerts have been found for Brilliant Violet 750(TM) anti-mouse/human CD11b.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Huang X, et al. (2026) Opposing functions of distinct regulatory T cell subsets in colorectal cancer. Immunity, 59(1), 145.

Izzati FN, et al. (2025) Presentation of immunoregulatory sialoglycans on T cells is divergent between mice and humans. Cell reports, 44(7), 115933.

Koliesnik I, et al. (2025) An IL-12 partial agonist sustains intratumoral lymphocyte activation and detoxifies systemic IL-12 therapy. Cell reports, 45(1), 116757.

Whiteley AE, et al. (2024) Breast cancer exploits neural signaling pathways for bone-to-meninges metastasis. Science (New York, N.Y.), 384(6702), eadh5548.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity, 57(7), 1514.

Uzhachenko RV, et al. (2021) Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T??cells into mammary tumors. Cell reports, 35(1), 108944.

Dikiy S, et al. (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity, 54(5), 931.